Abstracts Archive - Page 2299 of 2425 - ACR Meeting Abstracts

Abstract Number: 1848 • 2012 ACR/ARHP Annual Meeting
Impact of Biologics On Total Knee Replacement and Total Hip Replacement Rates in Rheumatoid Arthritis Patients: Results From US Marketscan Database
Andrew S. Koenig¹, Jack Mardekian² and Sameer Kotak³, ¹Specialty Care, Pfizer Inc, Collegeville, PA, ²Pfizer Inc, New York, NY, ³Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Joint replacement surgery patterns continue to change in patients with rheumatoid arthritis (RA), possibly reflecting the widespread adoption of disease modifying antirheumatic drugs, earlier…
Abstract Number: 1849 • 2012 ACR/ARHP Annual Meeting
Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Bruno Fautrel¹, Benjamin Granger², Bernard Combe³, Francis Guillemin⁴, Alain Saraux⁵ and Xavier Le Loët⁶, ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁶Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Rapid radiographic progression (RRP) – i.e., increase of the Sharp/van der Heijde score (vSHS) ≥ 5 points during the 1st year – is a…
Abstract Number: 1850 • 2012 ACR/ARHP Annual Meeting
Association of Clinical Trial Characteristics with Positive Study Outcome Reporting in Randomized Controlled Trials of Rheumatoid Arthritis Therapy
Fatima M. Khan¹, Juan I. Lombeida², Horace Spencer³, Karina D. Torralba⁴, Winnie K. Pang⁴ and Nasim A. Khan⁵, ¹Rheumatology/Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, ²Mercy Medical Center, Rogers, AR, ³University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose: Randomized controlled trials (RCTs) are considered the best research design for assessing healthcare intervention. Concerns have been raised about the increased likelihood of positive…
Abstract Number: 1851 • 2012 ACR/ARHP Annual Meeting
Exploring the Relationship of Anti-Tumor Necrosis Factor Drugs and Methicillin Resistant Staphylococcus Aureus Nasal Colonization in Patients with Rheumatologic Conditions and Psoriasis
Daniel E. Kreutz¹, Santosh P. Reddy¹, Guy P. Fiocco², Colleen Colbert³ and Juhee Song⁴, ¹Internal Medicine, Scott & White Healthcare/Texas A&M University, Temple, TX, ²Division of Rheumatology, Scott & White Clinic, Temple, TX, ³Graduate Education, Scott & White Healthcare/Texas A&M University, Temple, TX, ⁴Statistics, Scott & White Healthcare/Texas A&M University, Temple, TX
Background/Purpose: Infection with methicillin-resistant Staphylococcus aureus (MRSA) is a source of significant morbidity/mortality. Health-care entities spend large amounts to prevent spread of MRSA. Most MRSA…
Abstract Number: 1852 • 2012 ACR/ARHP Annual Meeting
Tumour Necrosis Factor-Alpha Antagonists and Alopecia: A Case/Non-Case Study in a Nationwide Pharmacovigilance Database
Johana Béné¹, Guillaume Moulis², Marine Auffret³, Claire Fessier¹, Guillaume Lefevre⁴ and Sophie Gautier¹, ¹Lille University Hospital, Lille Pharmacovigilance Regional Centre, Lille, France, ²Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, ³Pharmacology, Lille University Hospital, Lille Pharmacovigilance Regional Centre, Lille, France, ⁴Lille University Hospital, Internal Medicine Department, Lille, France
Background/Purpose: Cases of alopecia occurring on TNF-alpha antagonists have been described. Nevertheless, no epidemiological study has been conducted to assess the link between TNF-alpha antagonists…
Abstract Number: 1853 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients’ Experiences of Medication Side Effects and Subsequent Decision Making about Medications
Yomei Shaw¹, Ilinca D. Metes², Susan L. Zickmund³, Dawn McBride², Kelly A. Reckley², Stephen R. Wisniewski⁴, Larry W. Moreland², Mark S. Roberts¹ and Marc C. Levesque², ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA
Background/Purpose: Medication adherence in rheumatoid arthritis (RA) patients can be influenced by their previous experiences with medication side effects. Negative experiences may lead patients to…
Abstract Number: 1854 • 2012 ACR/ARHP Annual Meeting
The Safety of Anti-TNF Biologic Agents in Rheumatoid Arthritis – A Meta-Analysis of 35 RCTs
Tzuyu Lin¹, Tatyana Shamliyan¹, Hyon Choi², Young Hee Rho³ and Karen Kuntz¹, ¹Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: The objectives of this systematic review were to study and update the safety of anti-TNF agents. We examined whether etanercept (ETN), compared to the…
Abstract Number: 1855 • 2012 ACR/ARHP Annual Meeting
Prevalence of Potential Drug-Drug and Drug-Condition Interactions in Fibromyalgia Patients Newly-Initiating Pregabalin or Duloxetine
Stephen Johnston¹, Margarita Udall², Joseph C. Cappelleri³, Barbara H. Johnson⁴, George Shrady⁴ and Stuart L. Silverman⁵, ¹Truven Health Analytics, Bethesda, MD, ²Pfizer Inc., New York, NY, ³Pfizer Inc., Groton, CT, ⁴Truven Health Analytics, Washington, DC, ⁵Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA
Background/Purpose: Drug-drug and drug-condition interactions (DDI/DCI) can present a significant challenge to the appropriate prescribing of drugs. The risk of DDI/DCI may be elevated in…
Abstract Number: 1856 • 2012 ACR/ARHP Annual Meeting
Burden of Adverse Events Associated with Immunosuppressant Therapy for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review
Alan Oglesby¹, Arthur Weinstein², Greg Dennis³, Alissa Shaul⁴, Tiffany Pokora⁴, Clark Paramore⁵, Lael Cragin⁶ and Siva Narayanan⁷, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Washington Hospital Center, Washington, DC, ³Human Genome Sciences, Inc., Rockville, MD, ⁴United BioSource Corporation, Bethesda, MD, ⁵United BioSource Corporation, Lexington, MA, ⁶United BioSource, Bethesda, MD, ⁷Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD
Background/Purpose: Past systematic literature reviews on adverse events (AEs) associated with immunosuppressants in patients with systemic lupus erythematosus (SLE) focused mostly on cyclophosphamide (oral: CYC;…
Abstract Number: 1857 • 2012 ACR/ARHP Annual Meeting
Identifying Core Symptom Domains in the Fibromyalgia Impact Questionnaire: Principal Component Analysis of Data From Milnacipran Clinical Studies
Philip J. Mease¹, Robert M. Bennett², Robert H. Palmer³ and Yong Wang⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, ³Forest Research Institute, Inc., Jersey City, NJ, ⁴Forest Research Institute, Jersey City, NJ
Background/Purpose: The Fibromyalgia Impact Questionnaire (FIQ) is a multidimensional instrument that encompasses many of the core domains recommended by OMERACT for evaluation in fibromyalgia (FM)…
Abstract Number: 1858 • 2012 ACR/ARHP Annual Meeting
Hypervigiliance in Fibromyalgia
Robert S. Katz¹, Ben J. Small², Susan Shott¹ and Sharon M. Ferbert³, ¹Rush University Medical Center, Chicago, IL, ²MacNeal Hospital, Berwyn, IL, ³Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL
Background/Purpose: Patients with fibromyalgia syndrome (FMS) experience severe chronic pain and usually are tender to touch. They are hyperactive to weather changes and stress. Do…
Abstract Number: 1819 • 2012 ACR/ARHP Annual Meeting
Predictors of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Anna Gramling¹, Kaleb Michaud², Harlan Sayles³, Frederick Wolfe⁴ and Michelene Hearth-Holmes⁵, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS, ⁵Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are at high risk for serious infection, including those caused by Streptococcus pneumoniae. Administration…
Abstract Number: 1820 • 2012 ACR/ARHP Annual Meeting
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Gardasil^®) and Autoimmune Disorders: Safety Assessment Using the Pharmacoepidemiologic General Research Extension System
Lamiae Grimaldi-Bensouda¹, Michel Rossignol², Elodie Aubrun¹, Pamela Leighton³, Didier Guillemot⁴, Alfred Mahr⁵, Jacques Benichou⁶, Paul-Henri Lambert⁷, Bertrand Godeau⁸ and Lucien Abenhaim⁹, ¹LA-SER, Paris, France, ²LA-SER, Centre for Risk Research, Montreal, Canada, ³LA-SER Europe Ltd., London, United Kingdom, ⁴Institut Pasteur (PhEMI)/ INSERM U657 & Université Paris-Ile de France Ouest, Paris, France, ⁵Internal Medicine, Hospital Saint-Louis, Paris, France, ⁶INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, Rouen, France, ⁷Centre of Vaccinology & neonatal immunology, University of Geneva, Geneva, Switzerland, ⁸Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ⁹LA-SER Europe Ltd, London, United Kingdom
Background/Purpose: This study investigated whether the human papillomavirus (HPV) vaccine [types 6, 11, 16, 18] is associated with a modified risk of autoimmune disorders (AIDs).…
Abstract Number: 1821 • 2012 ACR/ARHP Annual Meeting
Clinical Predictors of Methotrexate-Induced Liver Enzyme Elevation in Patients with Rheumatoid Arthritis in an Electronic Medical Record
Monica Ramirez¹, Bing Lu¹, Michelle A. Frits², Anne H. Fossel³, Katherine P. Liao⁴, Robert M. Plenge⁵, Jonathan S. Coblyn⁶, Nancy A. Shadick⁷ and Elizabeth W. Karlson⁴, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology/Immunology, Brigham & Womens Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Methotrexate (MTX) use for the treatment of rheumatoid arthritis (RA) has been associated with hepatotoxicity, and requires monitoring of liver transaminases. However, elevations in…
Abstract Number: 1822 • 2012 ACR/ARHP Annual Meeting
Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation in a National Cohort of Veterans
Gabriela Schmajuk¹, Yinghui Miao², Jinoos Yazdany³, Mary Margaretten⁴ and Michael Steinman², ¹Rheumatology, UCSF / San Francisco VA Medical Center, San Francisco, CA, ²Division of Geriatrics, UCSF, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The National Quality Forum recently endorsed a controversial quality measure that assesses liver toxicity monitoring for patients receiving oral methotrexate (MTX). Using national data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].